GlycoMimetics' GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia
In the ongoing clinical trial, GMI-1271 is being administered, along
with chemotherapy, to patients with relapsed or refractory AML as well
as those 60 years of age and older with newly diagnosed disease. Data
from this trial were presented in 2016 at meetings of the European
Hematology Association (EHA) and the American Society of
Hematology (ASH). In the trial, patients treated with GMI-1271 achieved
higher than expected remission rates and lower than expected 30- and
60-day mortality rates in early evaluations of patients with
relapsed/refractory AML as well as in newly diagnosed patients. In
The
"The FDA's granting to GMI-1271 of Breakthrough Therapy designation will
further help
About AML
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow.
AML is the most common type of acute leukemia in adults. Each year in
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate, GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517006262/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media